Capstone <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Cuts Convertible Note Conversion Price to $0.75
Capstone Therapeutics Corporation has announced an amendment to its previously disclosed debt transaction with an institutional investor. The company had issued senior secured convertible notes totaling up to approximately $10.9 million, with original principal amounts of $3.27 million and $3.54 million for notes issued in July and October 2025, respectively. Initially, the conversion prices for these notes were set at $1.72 (later reduced to $1.00) and $1.10 per share. On November 28, 2025, Capstone and the investor agreed to further reduce the conversion price to $0.75 for the remaining balance of the July 2025 note and for $1.77 million of the October 2025 note's principal. The company has registered a total of 8,388,336 shares of common stock for potential issuance upon conversion of these notes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-116037), on November 28, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。